Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations